India develops its first cervical cancer vaccine

[September 02, 2022]  NEW DELHI (Reuters) - The Serum Institute of India (SII), the world's biggest vaccine maker, has developed the country's first cervical cancer shot that will hit the market soon, the company and the government said on Thursday.

Cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020, according to the World Health Organization. About 90% of the new cases and deaths worldwide occurred in low- and middle-income countries that year.

Two human papillomavirus (HPV) types, 16 and 18, are responsible for at least 70% of cervical cancers, and India's Department of Biotechnology said the Indian vaccine would work on HPV types 16 and 18, as well as 6 and 11.

Merck & Co and GSK Plc are the main makers of HPV vaccines.

"The indigenously developed vaccine will make our country self-sufficient in curbing female mortality caused by cervical cancer," SII Chief Executive Adar Poonawalla said in a statement.

Adar Poonawalla, CEO of Serum Institute of India (SII), the world's biggest vaccine maker, speaks during an interview with Reuters in the Alpine resort of Davos, Switzerland May 23, 2022. REUTERS/Arnd Wiegmann/File Photo

He told reporters the vaccine would be out for sale in a few months, first for the Indian market and then the world. It may be priced between 200 rupees and 400 rupees ($2.51-$5.03) and the company will aim to produce about 200 million doses in two years, Reuters partner ANI cited Poonawalla as saying.

The vaccine will be administered via injection in two doses among 9-14 year olds and in three doses for those between 15 and 26.

($1 = 79.5275 Indian rupees)

(Reporting by Krishna N. Das, Editing by William Maclean)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.